B2i Digital

B2i Digital The Capital Markets Matchmaker℠. They need an integrated team that takes a wholistic approach to their company's capital raising and investor awareness goals.

B2i Digital partners with public companies, conferences, and advisors to connect investors and companies through digital marketing, investor conferences, and direct meetings. Our team brings together decades of experience from the disparate worlds of investor relations, investment banking and digital marketing. In the rapidly evolving capital markets landscape, CEOs can no longer rely on the typic

al siloed mentality and try to manage multiple vendors. Investors want accurate, factual, relevant, and timely information provided by the companies where they invest. No hype. Just facts. Plus, direct access to senior management. Our cross-functional team bridges the communication gap between CEOs and investors to meet the needs of both sides for a more transparent dialogue.

06/19/2026

Lakewood-Amedex Biotherapeutics, Inc. (Nasdaq: LABT) presents at the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences (OTC Markets Group) and Zacks Investment Research Small Cap Research, at 11:00 AM ET on Thursday, June 25, 2026.

The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum

To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5389333/lakewood-amedex-biotherapeutics-inc-nasdaq-labt?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC

Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76

Kelvin Cooper, PhD, CEO and Director, presents for Lakewood-Amedex. He brings more than 45 years across drug discovery and development, including three decades at Pfizer in senior pharmaceutical sciences roles, and holds 34 patents.

Lakewood-Amedex is focused on developing the next generation of topical antimicrobials to address significant unmet needs in the treatment of infectious diseases. The company is aiming for first-in-class commercialization of its lead compound, working to overcome the bacterial resistance crisis and potentially advance treatment of non-bacterial infectious diseases.

Learn more at https://lakewoodamedex.investorroom.com/overview.

Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

06/19/2026

Innovotech Inc. (OTCQB: IOTCF | TSXV: IOT) joins the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences (OTC Markets Group) and Zacks Investment Research Small Cap Research, at 10:30 AM ET on Thursday, June 25, 2026.

The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum

To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5389331/innovotech-inc-otcqb-iotcf-tsxv-iot?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC

Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76

Innovotech is a Canadian boutique contract research organization specializing in advanced laboratory services and commercializing proprietary technologies. A leader in biofilm science, the company offers antimicrobial testing, pharmaceutical analysis, and industrial laboratory solutions, including its widely used MBEC Assay kit for high-throughput antimicrobial and antibiotic testing, delivered through ISO-certified and GMP-accredited laboratories that meet FDA and Health Canada standards.

Learn more at https://innovotech.ca/investors/.

Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

06/19/2026

Firefighter-Owned All Risk Shield Selects CitroTech (NYSE: CITR) as Its Preferred Fire Inhibitor After Independent Testing of Top Wildfire Defense Products

CitroTech® (NYSE: CITR) and All Risk Shield, a firefighter and veteran-owned wildfire mitigation and structure hardening provider, announced a strategic partnership under which All Risk Shield has selected CitroTech as its preferred fire inhibitor for residential, commercial, and estate properties across California.

CitroTech is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/citrotech-1.

The selection followed independent testing commissioned by All Risk Shield:

• The testing compared the top five fire retardant products on the market for composition, occupational exposure, and environmental factors

• CitroTech was the only product in the test set with no detectable heavy metals above the laboratory’s reporting limits

• All Risk Shield will deploy CitroTech across its California service territory as part of a layered approach that includes defensible space creation, ember-resistant retrofits, and property-specific risk assessments

See the full announcement: https://ir.citrotech.com/single-news-releases/?storyId=6957618797055860

Separately, Northland Capital Markets initiated research coverage of CitroTech on June 11, 2026.

CitroTech Inc. is a specialty chemical company manufacturing environmentally-safe fire prevention solutions for homes, wood products, and wildland asset protection. The company is headquartered in Greenwood Village, Colorado, and listed on NYSE as CITR.

CitroTech Inc. is led by Chief Executive Officer Wes Bolsen. To learn more about CitroTech, visit https://www.citrotech.com. For investor inquiries, visit https://ir.citrotech.com.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

06/19/2026

IMUNON (Nasdaq: IMNN) presents its clinical-stage platform harnessing the body's natural mechanisms across a range of diseases at the Life Sciences Virtual Investor Forum on June 25 at 12:00 PM ET.

IMUNON, Inc. (Nasdaq: IMNN) presents at the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 12:00 PM ET on Thursday, June 25, 2026.

The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum

To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5389871/imunon-inc-nasdaq-imnn?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC

Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76

Stacy Lindborg, PhD, President, CEO, and Board Director, presents for IMUNON. She brings nearly 30 years of pharmaceutical and biotech experience spanning R&D, regulatory affairs, and executive management, with prior leadership roles at BrainStorm Cell Therapeutics, Biogen, and Eli Lilly.

IMUNON is a fully integrated, clinical-stage biotechnology company advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, a differentiating approach from conventional therapies.

Learn more at https://investors.imunon.com/.

Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

06/19/2026

Kelyniam Global (OTCID: KLYG) presents its custom cranial and craniofacial implants delivered within 24 to 48 hours at the Life Sciences Virtual Investor Forum on June 25 at 11:30 AM ET.

Kelyniam Global, Inc. (OTCID: KLYG) takes the stage at the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 11:30 AM ET on Thursday, June 25, 2026.

The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum

To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5389342/kelyniam-global-inc-otcid-klyg?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC

Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76

Terrance Kurtenbach, CFO, presents for Kelyniam. He joined the company in 2020 after a career with Deloitte, where he served as a US Global Managing Partner in Life Sciences and Healthcare Tax.

Kelyniam is an industry leader in delivering custom cranial and craniofacial implants within 24 to 48 hours of surgeon approval for rush and expedited cases, helping reduce hospital length of stay and the associated risk of infection. Designed and manufactured in the United States, its implants are built to high standards of precision, safety, and reliability.

Learn more at https://kelyniam.com/.

Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

06/19/2026

Phio Pharmaceuticals (NASDAQ: PHIO) to present its INTASYL® siRNA platform and PH-762 program at the Life Sciences Investor Forum on June 24-25, 2026.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) will participate in the Life Sciences Investor Forum on June 24-25, 2026. CEO and Chairman Robert Bitterman will present an overview of the Company’s INTASYL® siRNA gene silencing platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas, with a live presentation and Q&A on Thursday, June 25, 2026 at 3 PM EDT and one-on-one meetings across both days.

Phio Pharmaceuticals Corp. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/phio-pharmaceuticals.

INTASYL is a proprietary RNA interference platform designed to enhance the body’s immune cells to more effectively kill cancer cells. Phio’s lead clinical candidate, PH-762, silences the PD-1 gene implicated in various forms of skin cancer and was evaluated in a Phase 1b trial (NCT # 06014086) for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma as a potential non-surgical treatment.

“We look forward to participating in the Life Sciences Investor Forum, where we will discuss why we believe INTASYL represents a differentiated and promising approach in immuno-oncology,” said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.

Register for the event: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5389925/phio-pharmaceuticals-corp-nasdaq-phio

See the full release: https://phiopharma.com/phio-pharmaceuticals-announces-participation-in-the-life-sciences-investor-forum-on-june-24-25-2026/

Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company developing therapeutics through its proprietary INTASYL gene silencing technology. INTASYL compounds are designed to enhance the body’s immune cells to more effectively kill cancer cells, with lead candidate PH-762 advancing as a potential non-surgical treatment for skin cancers. Phio is led by Robert Bitterman, CEO and Chairman of the Board. Learn more at www.phiopharma.com. Discover more emerging growth Featured Companies at b2idigital.com.

Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

06/19/2026

Renforth Resources holds two Quebec deposits next to Agnico Eagle’s Canadian Malartic mine.

Nicole Brewster, President and CEO of Renforth Resources Inc. (CSE:RFR) gave investors an overview of the company’s two Quebec deposits at a May 21, 2026 Virtual Investor Conference. The Parbec gold project and the Victoria nickel polymetallic project both sit next to Agnico Eagle’s Canadian Malartic mine, with roads and hydropower lines already running to them.

Renforth Resources is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/renforth-resources-1

Brewster opened with a rundown of what Renforth holds: “Renforth holds two deposits. One is the Parbec gold deposit. The other is the Victoria nickel sulfide polymetallic deposit. Both deposits are contiguous to the Canadian Malartic mine held by Agnico Eagle. Both deposits are open pit.”

The presentation also covered:
• Both deposits described as open pit candidates, in a province where about 99% of electricity is hydroelectric
• The Parbec gold deposit sitting along the Cadillac Break, next to the Canadian Malartic mine
• The Victoria deposit hosting nickel, cobalt, platinum, and palladium alongside zinc, copper, silver, and gold
• A land package of more than 300 square kilometers with additional exploration targets

Renforth Resources is a Quebec focused mineral exploration company advancing the Parbec gold deposit and the Victoria nickel polymetallic deposit, both located next to Agnico Eagle’s Canadian Malartic mine. Renforth trades on the CSE as RFR, on the OTC as RFHRF, and on the Frankfurt Stock Exchange as 9RR.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

Disclosure: B2i Digital is a paid digital marketing and investor awareness service provider for Renforth Resources. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

06/19/2026

Abingdon Health plc (OTCQB: ABDXF | LSE: ABDX) presents at the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 10:00 AM ET on Thursday, June 25, 2026.

The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum

To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5389329/abingdon-health-plc-otcqb-abdxf-lse-abdx?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC

Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76

Dr. Chris Hand, Executive Chairman, presents for Abingdon Health alongside CFO Tom Hayes. Hand co-founded the company and brings 30 years in the medical diagnostics industry, particularly in rapid tests, while Hayes is a Chartered Accountant who qualified with Arthur Andersen & Co.

Abingdon Health is focused on making rapid testing accessible across industries, with one of Europe's largest manufacturing capacities. The company provides comprehensive, large-scale, end-to-end contract development and manufacturing of point-of-care and decentralized diagnostic rapid tests, aiming to become the largest rapid test partner in the world.

Learn more at https://www.abingdonhealth.com/investors/.

Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

06/19/2026

Prostatype Genomics AB (OTCQB: PGABF | Nasdaq Stockholm: PROGEN) opens day two of the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 9:30 AM ET on Thursday, June 25, 2026.

The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum

To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5389325/prostatype-genomics-ab-otcqb-pgabf-nasdaq-stockholm-progen?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC

Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76

Fredrik Rickman, CEO, presents for Prostatype Genomics. He holds a B.Sc. in Business Administration and Economics from the University of Lund and brings more than 30 years of international life science industry experience in leadership positions.

Prostate cancer is one of the most common forms of cancer, with approximately 1.3 million men diagnosed annually. Prostatype Genomics specializes in the development, manufacturing, and marketing of Prostatype, a prognostic genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer.

Learn more at https://www.prostatypegenomics.com/investor-relations/.

Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

Address

401 2nd Avenue
New York, NY
10010

Telephone

+12125794844

Website

Alerts

Be the first to know and let us send you an email when B2i Digital posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to B2i Digital:

Shortcuts

Share

Category